

University of Groningen

High prevalence and clonal dissemination of OXA-72-producing *Acinetobacter baumannii* in a Chinese hospital

Chen, Yong; Yang, Yuying; Liu, Lin; Qiu, Guangbin; Han, Xuelin; Tian, Shuguang; Zhao, Jingya; Chen, Fangyan; Grundmann, Hajo; Li, Haifeng

Published in:
BMC Infectious Diseases

DOI:
[10.1186/s12879-018-3359-3](https://doi.org/10.1186/s12879-018-3359-3)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2018

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Chen, Y., Yang, Y., Liu, L., Qiu, G., Han, X., Tian, S., Zhao, J., Chen, F., Grundmann, H., Li, H., Sun, J., & Han, L. (2018). High prevalence and clonal dissemination of OXA-72-producing *Acinetobacter baumannii* in a Chinese hospital: a cross sectional study. *BMC Infectious Diseases*, 18, [491].
<https://doi.org/10.1186/s12879-018-3359-3>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

RESEARCH ARTICLE

Open Access



High prevalence and clonal dissemination of OXA-72-producing *Acinetobacter baumannii* in a Chinese hospital: a cross sectional study

Yong Chen^{1†}, Yuying Yang^{2,3†}, Lin Liu^{1,4†}, Guangbin Qiu⁵, Xuelin Han¹, Shuguang Tian¹, Jingya Zhao¹, Fangyan Chen¹, Hajo Grundmann^{6,7}, Haifeng Li^{8*}, Jinke Sun^{2,3,9*} and Li Han^{1*}

Abstract

Background: Carbapenem resistance in *Acinetobacter baumannii* in China was mainly mediated by OXA-23-like carbapenemases, while OXA-24/40-like carbapenemases were rarely identified. OXA-72 is one variant of OXA-24/40-like carbapenemases. This study aimed to demonstrate the epidemiology and characterizations of OXA-72-producing *A. baumannii* in a Chinese hospital.

Methods: A total of 107 clinical *A. calcoaceticus*-*A. baumannii* (Acb) complex isolates were collected in a Chinese hospital during between 2014 and 2016. These isolates were identified using Vitek 2 system and *gyrB* multiplex PCR. Vitek 2 system was used for antibiotic susceptibility testing. Genes encoding for major classes of carbapenemases were investigated by PCR. Rep-PCR was used for genotyping of all the *A. baumannii* isolates. The risk factors for carriage of OXA-72-producing or OXA-23-producing *A. baumannii* were analyzed through univariate and multivariate logistic regression.

Results: Of the 107 Acb isolates collected, 101 isolates (94.4%) and 6 isolates (5.6%) were identified as *A. baumannii* and *A. pittii*, respectively. 78 *A. baumannii* isolates (77.2%) were carbapenem resistant and mainly cultured from intensive care unit (ICU). *bla*_{OXA-72} and *bla*_{OXA-23} genes were identified in 45(57.7%) and 33(42.3%) carbapenem-resistant *A. baumannii* (CRAB), respectively. Multivariate risk factor analyses showed that prior carbapenem usage and nasogastric intubation were significantly associated with carriage of OXA-72-producing *A. baumannii* or OXA-23-producing *A. baumannii*. Rep-PCR analysis showed that 9 and 22 Rep-PCR types were assigned to 78 CRAB isolates and 23 carbapenem-susceptible *A. baumannii* (CSAB) isolates, respectively. A higher diversity of Rep-PCR patterns was observed among OXA-72-producing *A. baumannii* isolates than OXA-23-producing *A. baumannii* isolates, but all of them belonged to the same clone complex. MLST analysis suggested that the OXA-72 isolates from this study correspond to CC92/CC2 clone complex.

(Continued on next page)

* Correspondence: 185117683@qq.com; sunjinke202@sina.com; hanlicdc@163.com

†Yong Chen, Yuying Yang and Lin Liu contributed equally to this work.

⁸Department of Hospital Infection Control, The 202nd Hospital of PLA, Shenyang 110003, China

²School of Public Health, Shenyang Medical College, Shenyang, China

¹Department of Hospital Infection Control, Chinese PLA Institute for Disease Control and Prevention, 20# Dongda Str, Beijing 100071, China

Full list of author information is available at the end of the article



© The Author(s). 2018 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.

(Continued from previous page)

Conclusions: This study demonstrates high prevalence and potential clonal spread of closely related genotypes of OXA-72-producing *A. baumannii* within a Chinese hospital. Continuous surveillance is necessary to monitor the dissemination of these strains in other healthcare settings to guide infection control policies in order to curb the spread of this bacterium.

Keywords: *Acinetobacter baumannii*, OXA carbapenemases, Risk factor, Molecular typing, Clone dissemination

Background

Acinetobacter is a gram-negative coccobacillus that has rapidly emerged as one of the most common nosocomial pathogens worldwide [1]. There are currently at least 31 described *Acinetobacter* genomic species [2], of which *A. calcoaceticus*, *A. baumannii*, *A. pittii*, and *A. nosocomialis* are very closely related, and difficult to distinguish from each other by phenotypic properties [3]. *A. calcoaceticus*-*A. baumannii* (Acb) complex has therefore been proposed to refer to these species [2]. Nevertheless, *A. baumannii* is the most clinically relevant and is notorious for its ability to accumulate diverse mechanisms of resistance [4, 5].

The carbapenem class of antibiotics is considered as the last-resort choice when treating *Acinetobacter* infections. However, an increasing prevalence of carbapenem resistance has been observed in clinical *A. baumannii* isolates from many parts of the world. Carbapenem-associated multiclass resistance among 55,330 U.S. *A. baumannii* isolates from The Surveillance Network database has increased from 20.6% in 2002 to 49.2% in 2008 [6]. In China, the resistance rate of clinical *A. baumannii* to carbapenem gradually increased from < 10% in 2000 to > 60% at present [7, 8]. The major mechanism of carbapenem resistance is production of OXA β -lactamases, which are clustered in three major groups, OXA-23-like, OXA-24/40-like, and OXA-58-like [9–11].

OXA-24/40 β -lactamase was first identified in *A. baumannii* from Spain in 1997 [12]. After that, A further 6 enzyme variants have since been discovered, including OXA-72 [11]. Unlike OXA-23-like, OXA-24/40 β -lactamases were less commonly identified in carbapenem resistant *Acinetobacter* spp. isolates [13]. A large surveillance of OXA-type β -lactamase gene clusters for a total of 2880 *Acinetobacter* spp. isolates collected from 23 Chinese provinces found that *bla*_{OXA-23-like} and *bla*_{OXA-24/40-like} genes were identified in 1316 isolates (45.7%) and 11 isolates (0.4%), respectively [14]. Therefore, OXA-24/40-like β -lactamases were only responsible for a small number of carbapenem-resistance isolates in China, their dissemination and epidemiology in healthcare settings deserves further surveillance and investigation.

This study aimed to demonstrate the occurrence, clinical manifestation and genotypic characterizations of OXA-72-producing *A. baumannii* in a Chinese hospital.

Methods

Study settings and isolates information

A total of 107 clinical Acb complex isolates from 107 patients were collected at a tertiary-care comprehensive hospital in northeastern China with 1800 beds, from Oct 2014 to Oct 2016. These isolates were recovered from various specimens including sputum, blood, urine, pleural fluid, secretions and throat swab sample. For each patient, only a single colony of the first isolate was selected for subsequent analysis. All the clinical isolates were stored at -80°C until use. Data for each isolate and each patient were obtained through review of microbiology lab results and medical records. Risk factor data, including ICU stay, presence of invasive procedures and antibiotic treatment, referred to those which were present before the isolation of the index *Acinetobacter* strains. All data were anonymously collected and interpreted.

Strain identification and in vitro antibiotic susceptibility testing

Identification of Acb complex isolates was initially performed using automated identification systems the VITEK 2 compact system (BioMérieux, Craponne, France). Further identification of the Acb complex to the species level was performed by *gyrB* multiplex PCR [15, 16].

In vitro susceptibilities to ampicillin-sulbactam, piperacillin-tazobactam, ceftazidime, cefepime, meropenem, imipenem, gentamicin, amikacin, ciprofloxacin, levofloxacin, colistin, minocycline were determined by the VITEK 2 compact system (BioMérieux, Craponne, France). *Escherichia coli* (ATCC 25922) and *Pseudomonas aeruginosa* (ATCC 27853) were used as quality control strains. Results were interpreted according to the Clinical and Laboratory Standards Institute (CLSI, 2016) guidelines.

Detection of carbapenemases genes

One white loop (1 μl) of 24 h plate culture of *Acinetobacter* bacteria was resuspended in 200 μl of sterilized and DNA free water. The bacterial suspensions were then heated for 10 min at 96°C and centrifuged 5 min at 13000 rpm. The supernatant was used as the genomic DNA for the following molecular experiments.

Genes encoding for major classes of A, B, and D carbapenemases for all the Acb isolates were investigated by PCR. The presence of *bla*_{OXA-23-like}, *bla*_{OXA-24-like}, *bla*_{OXA-51-like}

and *bla*_{OXA-58-like} genes were detected through multiplex PCR assay [17]. Metallo- β -lactamase encoding genes, *bla*_{NDM-like}, *bla*_{IMP-like} and *bla*_{VIP-like}, were detected with PCR conditions and primers as previously described [18]. The *bla*_{OXA-24-like} variant was further identified through PCR and DNA sequencing as described [19].

Molecular typing

Rep-PCR was used for genotyping of all the *A. baumannii* isolates, using the primer pair REP 1(5'-IIIGCGC CGICAGGC-3') and REP 2(5'-ACGTCTTATCAGGC CTAC-3') [20]. The conditions for PCR and the gel electrophoresis were the same as previously described [21]. Rep-PCR results of each isolate was compared to all of the other isolates in a pairwise manner, isolates with identical band patterns were considered to be of identical Rep-PCR types. A minimum spanning tree was created to show the differences between patterns through BioNumerics 6.6 software (Applied Maths, Kortrijk, Belgium). The spanning tree was limited to those patterns that differ by a single band, two Rep-PCR types that differ by two or more bands were connected. Nine *bla*_{OXA-24-like} gene positive representative isolates from each different Rep-PCR type were randomly chosen for multilocus sequence typing (MLST) analysis according to 'Pasteur' scheme [22].

A review of literature

Currently, there were two MLST schemes available for *Acinetobacter*. In order to differentiate between the two schemes, STs and CCs were designated as ST^B/CC^B for the Bartual scheme and ST^P/CC^P for the Pasteur scheme. A search of previous published papers giving the MLST results of OXA-24/40-like producing *Acinetobacter* spp. was conducted to illustrate the population structure of OXA-24/40 strains from different countries. The MLST data from 'Pasteur' scheme and 'Bartual' scheme were separately analyzed by Bionumerics 6.6 and presented as a minimum spanning tree for categorical data with default settings.

Statistical analysis

Statistical analyses were performed using SPSS 19.0 (IBM, Armonk, NY, USA). The comparisons of patients' characteristics were conducted by chi-square test or Mann-Whitney U test. The risk factors for carriage of *bla*_{OXA-72}-positive or *bla*_{OXA-23-like}-positive *A. baumannii* were analyzed through univariate and multivariate logistic regression. In multivariate logistic regression, ICU stay and length of ICU stay were not included as they were highly associated with many other predisposing factors, including invasive procedures and antibiotic use. The index of diversity and the 95% confidence intervals (CIs) were calculated as described previously [23]. *P* values < 0.05 are considered statistically significant.

Results

Of the 107 *Acinetobacter* isolates, 101 isolates (94.4%) and 6 isolates (5.6%) were identified as *A. baumannii* and *A. pittii*, respectively. Five *A. pittii* isolates were susceptible to all the antibiotics tested and one isolate exhibited an intermediate resistance phenotype to minocycline. Among the 101 *A. baumannii* isolates, 78 isolates (77.2%) were resistant to carbapenems (meropenem or imipenem). The rates of resistance to piperacilin/tazobactam, ampicillin/sulbactam, amikacin, gentamicin, ceftazidime, ciprofloxacin and levofloxacin in *A. baumannii* were all above 60%, as most of the carbapenem-resistance isolates exhibited a multidrug resistance phenotype. Four *A. baumannii* isolates were resistant to polymyxin.

The 107 *Acinetobacter* isolates were cultured from 71 male and 46 female patients. Fifty-one isolates were cultured from patients in ICU and all these isolates were carbapenem-resistant. The detection of carbapenemase genes showed that 33 (42.3%) of the 78 carbapenem-resistant *A. baumannii* (CRAB) were positive for the *bla*_{OXA-23-like} gene, while the other 45 isolates (57.7%) were positive for the *bla*_{OXA-24/40-like} gene. All these isolates harboured *bla*_{OXA-51-like} gene. DNA sequencing showed that all the *bla*_{OXA-24/40-like} amplicons belonged to *bla*_{OXA-72} (GenBank accession number

Table 1 Characteristics of 101 patients colonized or infected with *Acinetobacter baumannii* in a Chinese hospital

Characteristics	No. of patients colonized or infected with <i>A. baumannii</i>		χ^2	<i>P</i> values
	Carbapenem-resistant (n = 78)	Carbapenem-susceptible (n = 23)		
Age, median years(range)	77(21,94)	76(2,96)	–	0.463
Male Gender, n(%)	50(64.1)	19(82.6)	2.81	0.094
Length of hospital stay, median days (range)	11(1,3650)	8(1,1400)	–	0.786
ICU stay, n (%)	49(62.8)	1(4.3)	24.30	< 0.001
Associated with an infection, n(%)	67(85.9)	17(73.9)	1.07	0.302
All-cause mortality of patients 14 days after isolation of <i>A. baumannii</i> , n(%)	16(20.5)	4(17.4)	0.001	0.974

ICU intensive care unit

Table 2 Univariate logistic analysis of risk factors for carriage of OXA-72-producing *Acinetobacter baumannii* or OXA-23-producing *A. baumannii*

Characteristics	Control cases ^a (n = 23)	OXA-72 cases (n = 45)	OR(CI 95%)	P value	OXA-23 cases (n = 33)	OR(CI 95%)	P value
Age, median(range)	76(2,96)	78(28,94)	1.02(1.00,1.05)	0.081	78(21,90)	1.00(0.99,1.03)	0.460
Male gender, n(%)	22(75.9)	27(60.0)	0.32(0.09,1.08)	0.067	23(69.7)	0.48(0.13,1.79)	0.484
ICU stay, n (%)	1(4.3)	27(60.0)	33.00(4.08,267.04)	0.001	22(66.7)	44.00(5.23,370.52)	< 0.001
Length of stay in the ICU (days), median(range)	0(0,2)	5(0,100)	2.29(1.20,4.37)	0.012	3(0,100)	2.29(1.03,5.08)	0.042
Predisposing factors							
Urinary catheter	9(39.1)	27(60.0)	2.33(0.84,6.52)	0.106	23(69.7)	3.58(1.17,10.96)	0.026
Mechanical ventilation	2(8.7)	18(40.0)	7.00(1.46,33.59)	0.015	14(42.4)	7.74(1.55,38.56)	0.013
Central venous catheter	5(21.7)	14(31.1)	1.63(0.50,5.26)	0.417	17(51.5)	3.83(1.15,12.74)	0.029
Tracheostomy	1(4.3)	10(22.2)	6.29(0.75,52.56)	0.090	11(33.3)	11.00(1.31,92.63)	0.027
Transfusion	1(4.3)	5(11.1)	2.75(0.30,25.05)	0.369	7(21.2)	5.92(0.68,51.92)	0.108
Nasogastric intubation	4(17.4)	28(62.2)	7.82(2.27,26.91)	0.001	19(57.6)	6.45(1.79,23.19)	0.004
Cephalosporin	12(52.2)	15(33.3)	0.46(0.16,1.27)	0.136	12(36.4)	0.53(0.17,1.55)	0.242
β-lactam/β-lactamase inhibitor combinations	12(52.2)	24(53.3)	2.61(0.90,7.57)	0.077	12(36.4)	1.31(0.42,4.07)	0.645
Quinolone	3(13.0)	19(42.2)	4.87(1.26,18.79)	0.022	10(30.3)	2.90(0.70,12.02)	0.143
Carbapenem	4(17.4)	21(46.7)	4.16(1.22,14.18)	0.023	20(60.6)	7.31(2.02,26.40)	0.002

^aControl cases: 23 patients colonized or infected with carbapenem-susceptible *Acinetobacter baumannii*
ICU intensive care unit

MF781069). The *bla*_{OXA-58-like} gene was detected in one carbapenem-susceptible *A. baumannii* (CSAB) isolate, the MICs for imipenem and meropenem were 0.5 µg/ml and 0.25 µg/ml, respectively. None of these *Acinetobacter* isolates were positive for *bla*_{IMP-like}, *bla*_{VIM-like} or *bla*_{NDM-like} genes.

Eighty-four (83.2%) of 101 *A. baumannii* isolates were associated with an infection (primarily low respiratory tract infection) and antibiotic treatment, while the other 27 isolates were just colonized. The characteristics of 101 patients colonized or infected with *A. baumannii* were shown in Table 1. There were no significant differences over age and gender distribution among patients colonized or infected with CRAB and CSAB strains. More than 60% of the CRAB patients stayed at ICU at the time of bacteria isolation, while only one CSAB patient stayed at ICU.

The results of univariate logistic analysis showed that there were many common risk factors for carriage of OXA-72-producing *A. baumannii* or OXA-23-producing

A. baumannii, such as ICU stay, mechanical ventilation, nasogastric intubation and carbapenem treatment (Table 2). In multivariate analysis, prior carbapenem usage and nasogastric intubation were significantly associated with carriage of OXA-72-producing *A. baumannii* or OXA-23-producing *A. baumannii*. An additional risk factor, urinary catheter, was also significantly associated with carriage of *bla*_{OXA-23-like}-positive *A. baumannii* (Table 3).

The results of Rep-PCR patterns and corresponding strain information for the 101 *A. baumannii* were shown in Table 4. In total, 9 Rep-PCR types were assigned to 78 CRAB isolates, while 22 Rep-PCR types were assigned to 23 CSAB isolates. The index of diversity (DI) for CRAB was 0.750 (95% CI: 0.671–0.829), which was significantly lower than for CSAB (DI = 0.996, 95% CI: 0.986–1.006). Twenty-six and 7 OXA-23-producing *A. baumannii* isolates were identified as Rep-PCR type 1 and 2, respectively, while 45 OXA-72-producing *A. baumannii* isolates

Table 3 Multivariate logistic analysis of risk factors for carriage of OXA-72-producing *Acinetobacter baumannii* or OXA-23-producing *A. baumannii*

Characteristics	OXA-72 cases		OXA-23 cases	
	OR(CI 95%)	P value	OR(CI 95%)	P value
Urinary catheter	–	–	4.94(1.61–21.07)	0.031
Nasogastric intubation	7.65(2.14,27.36)	0.002	7.95(1.79–35.34)	0.006
Carbapenem usage	4.02(1.07,15.06)	0.039	10.05(2.21–45.58)	0.003

Table 4 The Rep-PCR type, MLST type, presence of carbapenemase genes and antimicrobial resistance profile of 101 *Acinetobacter baumannii* isolates

Isolate ID	Rep-PCR type	MLST type	Carbapenemase genes	Antimicrobial resistance profile											
				IMP	MEM	CAZ	FEP	AMK	GEN	CIP	LVX	TZP	SAM	MH	COL
N1312	1	NA	<i>bla</i> _{OXA-23}	R	R	R	R	R	R	R	R	R	R	S	S
N1314	1	NA	<i>bla</i> _{OXA-23}	R	R	R	I	R	R	R	R	R	R	S	S
N1316	1	NA	<i>bla</i> _{OXA-23}	R	R	R	R	R	R	R	R	R	R	S	S
N1318	1	NA	<i>bla</i> _{OXA-23}	R	R	R	I	S	R	R	R	R	I	S	S
N1352	1	NA	<i>bla</i> _{OXA-23}	R	R	R	R	R	R	R	I	R	R	S	S
N1359	1	NA	<i>bla</i> _{OXA-23}	R	R	R	R	R	R	R	I	R	R	S	S
N1362	1	NA	<i>bla</i> _{OXA-23}	R	R	R	R	R	R	R	R	R	R	S	S
N1369	1	NA	<i>bla</i> _{OXA-23}	R	R	R	R	R	I	R	I	R	R	S	S
N1371	1	NA	<i>bla</i> _{OXA-23}	R	R	R	R	R	R	R	I	R	R	S	S
N1383	1	NA	<i>bla</i> _{OXA-23}	R	R	R	R	R	R	R	R	R	R	S	S
N1384	1	NA	<i>bla</i> _{OXA-23}	R	R	R	R	R	R	R	R	R	R	S	S
N1386	1	NA	<i>bla</i> _{OXA-23}	R	R	R	R	R	R	R	I	R	R	S	R
N1395	1	NA	<i>bla</i> _{OXA-23}	R	R	R	R	R	R	R	R	R	R	S	S
N1396	1	NA	<i>bla</i> _{OXA-23}	R	R	R	R	R	R	R	R	R	R	S	S
N1398	1	NA	<i>bla</i> _{OXA-23}	I	R	R	R	R	R	R	R	R	I	S	S
N1401	1	NA	<i>bla</i> _{OXA-23}	R	R	R	R	R	R	R	R	R	I	S	S
N1407	1	NA	<i>bla</i> _{OXA-23}	R	R	R	R	R	R	R	R	R	R	S	S
N741	1	NA	<i>bla</i> _{OXA-23}	R	R	R	R	R	R	R	R	R	R	S	S
N747	1	NA	<i>bla</i> _{OXA-23}	R	R	R	I	R	R	R	R	R	S	I	S
N748	1	NA	<i>bla</i> _{OXA-23}	R	R	R	R	R	R	R	R	S	R	I	S
N749	1	NA	<i>bla</i> _{OXA-23}	R	R	R	R	R	R	R	R	R	R	S	S
N751	1	NA	<i>bla</i> _{OXA-23}	R	R	R	R	R	R	R	R	R	R	S	S
N752	1	NA	<i>bla</i> _{OXA-23}	R	R	R	R	R	R	R	R	R	R	I	S
N756	1	NA	<i>bla</i> _{OXA-23}	R	R	R	I	R	R	R	R	R	S	S	S
N762	1	NA	<i>bla</i> _{OXA-23}	R	R	R	R	R	R	R	R	R	R	I	S
N764	1	NA	<i>bla</i> _{OXA-23}	R	R	R	R	R	R	R	R	R	R	I	S
N1304	1	NA	<i>bla</i> _{OXA-72}	R	R	R	S	R	R	R	I	R	I	S	S
N1307	1	2	<i>bla</i> _{OXA-72}	R	R	R	I	R	R	R	R	R	I	S	S
N1309	1	NA	<i>bla</i> _{OXA-72}	R	R	R	R	R	R	R	I	R	R	S	S
N1311	1	NA	<i>bla</i> _{OXA-72}	R	R	R	I	R	R	R	I	R	I	S	S
N1315	1	NA	<i>bla</i> _{OXA-72}	R	R	R	R	R	R	R	R	R	R	S	S
N743	1	NA	<i>bla</i> _{OXA-72}	R	R	R	R	R	R	R	R	R	R	R	S
N745	1	NA	<i>bla</i> _{OXA-72}	R	R	R	I	R	R	R	R	R	I	I	S
N750	1	NA	<i>bla</i> _{OXA-72}	R	R	R	I	R	R	R	R	R	R	I	S
N754	1	NA	<i>bla</i> _{OXA-72}	R	R	R	I	R	R	R	R	R	I	S	S
N1412	2	NA	<i>bla</i> _{OXA-23}	I	R	R	R	R	R	R	R	R	R	S	S
N1419	2	NA	<i>bla</i> _{OXA-23}	I	R	R	R	R	R	R	R	R	R	S	S
N1420	2	NA	<i>bla</i> _{OXA-23}	R	R	R	R	R	R	R	R	R	S	S	S
N1424	2	NA	<i>bla</i> _{OXA-23}	I	R	R	R	R	R	R	R	R	R	S	S
N1428	2	NA	<i>bla</i> _{OXA-23}	R	R	R	R	R	R	R	R	R	I	S	S
N1447	2	NA	<i>bla</i> _{OXA-23}	R	R	R	R	R	R	R	I	R	R	S	S
N1449	2	NA	<i>bla</i> _{OXA-23}	R	R	R	R	R	R	R	I	R	R	S	S

Table 4 The Rep-PCR type, MLST type, presence of carbapenemase genes and antimicrobial resistance profile of 101 *Acinetobacter baumannii* isolates (Continued)

Isolate ID	Rep-PCR type	MLST type	Carbapenemase genes	Antimicrobial resistance profile											
				IMP	MEM	CAZ	FEP	AMK	GEN	CIP	LVX	TZP	SAM	MH	COL
N1372	2	NA	<i>bla</i> _{OXA-72}	R	R	R	I	R	R	R	R	R	R	I	S
N1411	2	NA	<i>bla</i> _{OXA-72}	R	R	R	I	R	R	R	R	R	R	S	S
N1425	2	2	<i>bla</i> _{OXA-72}	R	R	R	S	R	R	R	R	R	I	S	S
N1446	2	NA	<i>bla</i> _{OXA-72}	R	R	R	I	R	R	R	R	R	R	S	S
N1451	2	NA	<i>bla</i> _{OXA-72}	R	R	R	R	R	R	R	R	R	R	I	S
N1348	3	NA	<i>bla</i> _{OXA-72}	R	R	R	I	R	R	R	R	R	R	S	S
N1349	3	NA	<i>bla</i> _{OXA-72}	R	R	R	I	R	R	R	R	R	R	S	S
N1368	3	NA	<i>bla</i> _{OXA-72}	R	R	R	I	R	R	R	R	R	R	S	S
N1376	3	NA	<i>bla</i> _{OXA-72}	R	R	R	S	R	R	R	R	R	R	S	S
N1378	3	NA	<i>bla</i> _{OXA-72}	R	R	R	I	R	R	R	R	R	R	S	S
N1421	3	2	<i>bla</i> _{OXA-72}	R	R	R	I	R	R	R	R	R	I	S	S
N1427	3	NA	<i>bla</i> _{OXA-72}	R	R	R	I	R	R	R	R	R	R	S	S
N1429	3	NA	<i>bla</i> _{OXA-72}	R	R	R	I	S	S	R	I	R	R	S	S
N1432	3	NA	<i>bla</i> _{OXA-72}	R	R	R	I	R	R	R	R	R	S	S	S
N1436	3	NA	<i>bla</i> _{OXA-72}	R	R	R	R	R	R	R	R	R	R	S	S
N1437	3	NA	<i>bla</i> _{OXA-72}	R	R	R	I	R	R	R	R	R	R	S	S
N1365	4	NA	<i>bla</i> _{OXA-72}	R	R	R	I	R	R	R	R	R	R	S	S
N1366	4	NA	<i>bla</i> _{OXA-72}	R	R	R	R	R	R	R	R	R	R	S	S
N1422	4	2	<i>bla</i> _{OXA-72}	R	R	R	S	R	R	R	I	R	I	S	S
N1434	4	NA	<i>bla</i> _{OXA-72}	R	R	R	I	R	R	R	R	R	R	S	S
N1361	5	NA	<i>bla</i> _{OXA-72}	R	R	R	I	R	R	R	R	R	R	S	S
N1375	5	NA	<i>bla</i> _{OXA-72}	R	R	R	R	R	I	R	R	R	R	S	S
N1380	5	NA	<i>bla</i> _{OXA-72}	R	R	R	S	R	R	R	R	R	R	S	S
N1381	5	NA	<i>bla</i> _{OXA-72}	R	R	R	S	R	R	R	R	R	R	S	S
N1397	5	2	<i>bla</i> _{OXA-72}	R	R	R	I	R	R	R	R	R	R	S	S
N1400	5	NA	<i>bla</i> _{OXA-72}	R	R	R	I	R	R	R	R	R	R	S	S
N1350	6	NA	<i>bla</i> _{OXA-72}	R	R	R	I	R	R	R	R	R	R	S	S
N1353	6	2	<i>bla</i> _{OXA-72}	R	R	R	R	R	R	R	R	R	R	S	S
N1370	6	NA	<i>bla</i> _{OXA-72}	R	R	R	I	R	R	R	R	R	R	I	S
N1391	7	2	<i>bla</i> _{OXA-72}	R	R	R	R	R	R	R	R	R	R	S	S
N1357	8	2	<i>bla</i> _{OXA-72}	R	R	S	S	S	R	R	R	I	S	S	S
N1374	8	NA	<i>bla</i> _{OXA-72}	R	R	R	I	R	R	R	R	R	R	S	S
N1379	8	NA	<i>bla</i> _{OXA-72}	R	R	R	I	R	R	R	R	R	R	S	S
N1392	8	NA	<i>bla</i> _{OXA-72}	R	R	R	S	R	R	R	R	R	R	S	S
N1409	8	NA	<i>bla</i> _{OXA-72}	R	R	R	S	R	R	R	I	R	I	S	S
N1382	9	2	<i>bla</i> _{OXA-72}	R	R	R	S	R	R	R	R	R	R	S	S
N1415	10	NA	None	S	S	S	S	S	S	S	S	S	S	S	S
N1441	11	NA	None	S	S	S	S	S	R	S	S	S	R	S	S
N1443	12	NA	None	S	S	S	S	S	S	S	S	S	S	S	S
N1408	13	NA	None	S	S	S	S	S	S	S	S	S	S	S	S
N1306	14	NA	None	S	S	S	S	S	S	S	S	S	S	S	S
N1414	15	NA	None	S	S	S	S	S	S	S	S	S	S	S	S

Table 4 The Rep-PCR type, MLST type, presence of carbapenemase genes and antimicrobial resistance profile of 101 *Acinetobacter baumannii* isolates (Continued)

Isolate ID	Rep-PCR type	MLST type	Carbapenemase genes	Antimicrobial resistance profile											
				IMP	MEM	CAZ	FEP	AMK	GEN	CIP	LVX	TZP	SAM	MH	COL
N1363	16	NA	None	S	S	S	S	S	S	S	S	S	S	S	S
N1389	17	NA	None	S	S	S	S	S	S	S	S	S	S	S	S
N1405	18	NA	None	S	S	S	S	S	S	S	S	S	S	S	S
N1406	18	NA	None	S	S	S	S	S	S	S	S	S	S	S	R
N1377	19	NA	None	S	S	R	R	R	R	R	R	R	R	S	S
N1390	20	NA	<i>bla_{OXA-58}</i>	S	S	S	S	S	R	S	S	S	S	S	S
N1448	21	NA	None	S	S	S	S	S	R	R	R	S	S	S	R
N1354	22	NA	None	S	S	S	S	S	S	S	S	S	S	S	S
N746	23	NA	None	S	S	S	S	S	S	S	S	S	I	S	S
N1364	24	NA	None	S	S	S	S	S	S	S	S	S	S	S	S
N1393	25	NA	None	S	S	S	S	S	S	S	S	S	S	S	S
N1351	26	NA	None	S	S	S	S	S	S	S	S	S	S	S	S
N1399	27	NA	None	S	S	S	S	S	S	S	S	S	S	S	S
N1305	28	NA	None	S	S	S	S	S	S	S	S	S	S	S	S
N1387	29	NA	None	S	S	S	S	S	S	S	S	S	S	S	S
N744	30	NA	None	S	S	S	S	S	S	S	S	S	S	S	R
N1423	31	NA	None	S	S	S	S	S	S	S	S	S	S	S	S

NA not available, IMP imipenem, MEM meropenem, CAZ ceftazidime, FEP cefepime, AMK amikacin, GEN gentamicin, CIP ciprofloxacin, LVX levofloxacin, TZP piperacillin-tazobactam, SAM ampicillin-sulbactam, MH minocycline, COL colistin, R resistant, I intermediate, S susceptible

were distributed in the 9 Rep-PCR types. Minimum spanning tree analysis of Rep-PCR patterns showed that all the 78 CRAB isolates were clustered into one clone complex, while most of the CSAB isolates were not connected to each other (Fig. 1). MLST analysis showed that all the 9 representative OXA-72 isolates in this study belong to ST2 (Table 4).

A literature review of previous published MLST data showed that there were at least 19 ST types (Bartual scheme) for 29 OXA-24/40-like producing *Acinetobacter* spp. isolates from 11 countries and 21 ST types (Pasteur scheme) for 52 OXA-24/40-like producing *Acinetobacter* spp. isolates from 15 countries. Minimum spanning tree analysis of these isolates based on two different MLST schemes was shown in Fig. 2, which suggested that CC92^B/CC2^P represented the predominant clone for the OXA-24/40-like producing *Acinetobacter* spp. isolates from around the world.

Discussions

Carbapenem-resistant *Acinetobacter* spp. (mainly CRAB) are increasingly recognized as major nosocomial pathogens and considered to be serious threat for human health by US Centers for Disease Control and Prevention and World Health Organization [24, 25]. OXA-23-like carbapenemases were the main reason for the high prevalence

and wide dissemination of CRAB from many parts of the world, including China [14, 26, 27]. OXA-24/40-like carbapenemases, which have been reported to be associated with outbreak of nosocomial infection in United States, Spain, Turkey and Ecuador [28–31], accounted for only a small part of CRAB in China [14, 32]. OXA-72, which was first identified in 2004 in an *A. baumannii* isolate from Thailand, belonged to one of the most important variant of OXA-24/40-like carbapenemases [29]. This study reported firstly a high prevalence and clonal dissemination of OXA-72-producing *A. baumannii* in a hospital from northeastern China.

Carbapenem resistance in *A. baumannii* was not significantly associated with 14-day mortality in this study (Table 1), which is in accordance with previous studies [33, 34]. However, carbapenem resistance limits the available therapeutic agents, makes the infection difficult to treat, and might be associated with an additional cost of hospitalization [34]. In this study, there was no significant difference over length of hospital stay for carbapenem resistance and susceptible *A. baumannii*, which might be related with the limited sample size.

In vitro antimicrobial susceptibility testing showed that OXA-72-producing *A. baumannii* and OXA-23-producing *A. baumannii* exhibited similar multidrug resistance profile, suggesting that they could not be differentiated through





Fig. 1 Minimum spanning tree of 101 *Acinetobacter baumannii* isolates based on Rep-PCR patterns. Each circle represents one unique genotype. OXA-72-producing carbapenem-resistant *A. baumannii* (CRAB), OXA-23-producing CRAB and carbapenem-susceptible *A. baumannii* (CSAB) isolates are indicated with red, green, and blue colors, respectively. The size of each circle corresponds to the number of isolates. The lines connecting the circles indicate those patterns that differ by a single band. R: carbapenem-resistant strains. S: carbapenem-susceptible strains

detection of antimicrobial phenotype. The risk factor analyses implicated that admitted into ICU and length of ICU stay were the most important risk factors for carriage of OXA-72-producing *A. baumannii* and OXA-23-producing *A. baumannii*, as ICU patients are always critical ill and subjected to a lot of risk factors for the acquisition of multi-drug resistance organisms (MDROs) [35]. When ICU stay was removed for multivariable analyses, nasogastric intubation and carbapenem use were significantly associated with acquisition of both classes of CRAB, which is in accordance with previous studies [36–38]. The reason for why urinary catheter was significantly associated with carriage of OXA-23-producing *A. baumannii*,

but not OXA-72-producing *A. baumannii* deserves further investigation. One possible explanation was that the complex conditions and combined therapy of ICU patients compromised the accuracy of multiple logistics analysis, urinary catheter might be just an indicator for critical ill patients who have a high probability of acquiring certain MDROs through contaminated environment or nursing behavior.

CC92^B/CC2^P was by far the largest and most widely distributed *A. baumannii* clone in the world, especially among OXA-23-producing *A. baumannii* [27, 39, 40]. Although not so widely disseminated, CC92^B/CC2^P was still the most important clone in OXA-24/40-producing *A. baumannii*



(Fig. 2). The Rep-PCR and MLST analysis of *A. baumannii* in this study suggested that OXA-72-producing and OXA-23-producing *A. baumannii* isolates were genetically related and belonged to the same clone, CC92^B/CC2^P. It seems that OXA-72-producing *A. baumannii* has already become endemic in the ICU since 2014, as most of these isolates were continuously cultured without obvious clustering of isolation time. Enhanced infection control measures, such as hand hygiene education programs, environmental cleaning, antimicrobial stewardship, contact precautions [41], have to be implemented in ICU of this hospital in order to reduce the wide spread of high risk clone, CC92^B/CC2^P, which represents the most prevalent clone of CRAB in Chinese hospitals.

There are some limitations for this study. The first is the inclusion criteria of Acb complex strains, it has been demonstrated that a single patient may have more than one genetic type of *Acinetobacter* [42, 43]. To avoid the problem of duplicate data, this study adopted a simple inclusion method of allowing only a single isolate per patient. It might limit the ability to monitor the dynamic changes and complex conditions in patients who may be at particular risk of acquiring antibiotic resistant strains through cross-infection or the development of resistance during antibiotic treatment [44]. Another limitation comes from the design of this study, as this is just an one-center

study, the epidemiological characterizations of OXA-72 strains in this study might not be generalized to other healthcare settings in China.

Conclusions

This study described firstly a high prevalence of OXA-72-producing *A. baumannii* in ICU of a Chinese hospital, which have circulated in this ICU through clonal dissemination for at least two years. Strict infection control measures must be implemented to contain the ongoing dissemination of OXA carbapenemases-producing *A. baumannii* in Chinese ICUs.

Abbreviations

Acb: *Acinetobacter calcoaceticus*-*A. baumannii*; CC: Clone complex; CRAB: Carbapenem-resistant *A. baumannii*; CSAB: Carbapenem-susceptible *A. baumannii*; DI: Index of diversity; ICU: Intensive care unit; MDROs: Multidrug resistance organisms; MLST: Multilocus sequence typing; ST: Sequence type

Funding

The study was supported by a grant from the National Key Program for Infectious Diseases of China (2018ZX10733402), Beijing Natural Science Foundation (7172157) and the Beijing Nova Program (Z181100006218107).

Availability of data and materials

The datasets used and/or analyzed during the current study available from the corresponding author on reasonable request.

Authors' contributions

LH, HL, JS and HG conceptualized and designed the study. YY, LL, GQ, XH, ST, JZ, FC were involved in the data collection, generation, and performed

laboratory analysis. YC, YY and LL analyzed and interpreted the data, drafted the manuscript. LH and HG revised the manuscript critically for important intellectual content. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The study was approved by the institutional ethics committees of the Academy of Military Medical Sciences of the Chinese People's Liberation Army, Beijing, China. Because the study was epidemiological without any interventions and all the data were collected and analyzed anonymously, the requirement for informed consent was waived.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

¹Department of Hospital Infection Control, Chinese PLA Institute for Disease Control and Prevention, 20# Dongda Str, Beijing 100071, China. ²School of Public Health, Shenyang Medical College, Shenyang, China. ³The 202nd Hospital of PLA, Shenyang 110003, China. ⁴Laboratory of Tropical Biomedicine Technology, School of Tropical Medicine and Laboratory Medicine, Hainan Medical University, Haikou, China. ⁵Department of Clinical Microbiology, The 202nd Hospital of PLA, Shenyang, China. ⁶Department of Infection Prevention and Hospital Hygiene, Faculty of Medicine, University of Freiburg, Freiburg, Germany. ⁷Department of Medical Microbiology, University Medical Center Groningen, Rijksuniversiteit Groningen, Groningen, The Netherlands. ⁸Department of Hospital Infection Control, The 202nd Hospital of PLA, Shenyang 110003, China. ⁹Chinese PLA 202 Hospital, Shenyang 110003, China.

Received: 17 November 2017 Accepted: 23 August 2018

Published online: 29 September 2018

References

- Lima AL, Oliveira PR, Paula AP. *Acinetobacter* infection. N Engl J Med. 2008;358(12):1271–81.
- Peleg AY, Seifert H, Paterson DL. *Acinetobacter baumannii*: emergence of a successful pathogen. Clin Microbiol Rev. 2008;21(3):538–82.
- Nemec A, Krizova L, Maignerova M, van der Reijden TJ, Deschaght P, Passet V, et al. Genotypic and phenotypic characterization of the *Acinetobacter calcoaceticus*-*Acinetobacter baumannii* complex with the proposal of *Acinetobacter pittii* sp. nov. (formerly *Acinetobacter* genomic species 3) and *Acinetobacter nosocomialis* sp. nov. (formerly *Acinetobacter* genomic species 13TU). Res Microbiol. 2011;162(4):393–404.
- Antunes LC, Visca P, Towner KJ. *Acinetobacter baumannii*: evolution of a global pathogen. Pathog and Dis. 2014;71(3):292–301.
- Doi Y, Murray GL, Peleg AY. *Acinetobacter baumannii*: evolution of antimicrobial resistance-treatment options. Semin Respir Crit Care Med. 2015;36(1):85–98.
- Mera RM, Miller LA, Amrine-Madsen H, Sahm DF. *Acinetobacter baumannii* 2002–2008: increase of carbapenem-associated multiclass resistance in the United States. Microb Drug Resist. 2010;16(3):209–15.
- Xiao YH, Giske CG, Wei ZQ, Shen P, Heddini A, Li LJ. Epidemiology and characteristics of antimicrobial resistance in China. Drug Resist Updat. 2011;14(4–5):236–50.
- Hu FP, Guo Y, Zhu DM, Wang F, Jiang XF, Xu YC, et al. Resistance trends among clinical isolates in China reported from CHINET surveillance of bacterial resistance, 2005–2014. Clin Microbiol Infect. 2016;22(Suppl 1):S9–14.
- Docquier JD, Mangani S. Structure-function relationships of class D Carbapenemases. Curr Drug Targets. 2016;17(9):1061–71.
- Antunes NT, Lamoureux TL, Toth M, Stewart NK, Frase H, Vakulenko SB. Class D -lactamases: are they all Carbapenemases? Antimicrob Agents Chemother. 2014;58(4):2119–25.
- Evans BA, Amyes SG. OXA beta-lactamases. Clin Microbiol Rev. 2014;27(2):241–63.
- Bou G, Oliver A, Martinez-Beltran J. OXA-24, a novel class D beta-lactamase with carbapenemase activity in an *Acinetobacter baumannii* clinical strain. Antimicrob Agents Chemother. 2000;44(6):1556–61.
- Mendes RE, Bell JM, Turnidge JD, Castanheira M, Jones RN. Emergence and widespread dissemination of OXA-23, –24/40 and –58 carbapenemases among *Acinetobacter* spp. in Asia-Pacific nations: report from the SENTRY Surveillance Program. J Agents Chemother. 2009;63(1):55–9.
- Ji S, Chen Y, Ruan Z, Fu Y, Ji J, Fu Y, et al. Prevalence of carbapenem-hydrolyzing class D beta-lactamase genes in *Acinetobacter* spp. isolates in China. Eur J Clin Microbiol Infect Dis. 2014;33(6):989–97.
- Higgins PG, Lehmann M, Wisplinghoff H, Seifert H. gyrB multiplex PCR to differentiate between *Acinetobacter calcoaceticus* and *Acinetobacter* genomic species 3. J Clin Microbiol. 2010;48(12):4592–4.
- Higgins PG, Wisplinghoff H, Krut O, Seifert H. A PCR-based method to differentiate between *Acinetobacter baumannii* and *Acinetobacter* genomic species 13TU. Clin Microbiol Infect. 2007;13(12):1199–201.
- Woodford N, Ellington MJ, Coelho JM, Turton JF, Ward ME, Brown S, et al. Multiplex PCR for genes encoding prevalent OXA carbapenemases in *Acinetobacter* spp. Int J Antimicrob Agents. 2006;27(4):351–3.
- Poirer L, Walsh TR, Cuvillier V, Nordmann P. Multiplex PCR for detection of acquired carbapenemase genes. Diagn Microbiol Infect Dis. 2011;70(1):119–23.
- Afzal-Shah M, Woodford N, Livermore DM. Characterization of OXA-25, OXA-26, and OXA-27, molecular class D beta-lactamases associated with carbapenem resistance in clinical isolates of *Acinetobacter baumannii*. Antimicrob Agents Chemother. 2001;45(2):583–8.
- Vila J, Marcos MA, Jimenez de Anta MT. A comparative study of different PCR-based DNA fingerprinting techniques for typing of the *Acinetobacter calcoaceticus*-*A. baumannii* complex. J Med Microbiol. 1996;44(6):482–9.
- Bou G, Cervero G, Dominguez MA, Quereda C, Martinez-Beltran J. PCR-based DNA fingerprinting (rep-PCR, AP-PCR) and pulsed-field gel electrophoresis characterization of a nosocomial outbreak caused by imipenem- and meropenem-resistant *Acinetobacter baumannii*. Clin Microbiol Infect. 2000;6(12):635–43.
- Diancourt L, Passet V, Nemec A, Dijkshoorn L, Brisse S. The population structure of *Acinetobacter baumannii*: expanding multiresistant clones from an ancestral susceptible genetic pool. PLoS One. 2010;5(4):e10034.
- Grundmann H, Hori S, Tanner G. Determining confidence intervals when measuring genetic diversity and the discriminatory abilities of typing methods for microorganisms. J Clin Microbiol. 2001;39(11):4190–2.
- Kim UJ, Kim HK, An JH, Cho SK, Park KH, Jang HC. Update on the epidemiology, treatment, and outcomes of Carbapenem-resistant *Acinetobacter* infections. Chonnam Med J. 2014;50(2):37–44.
- Wernli D, Jorgensen PS, Harbarth S, Carroll SP, Laxminarayan R, Levrat N, et al. Antimicrobial resistance: the complex challenge of measurement to inform policy and the public. PLoS Med. 2017;14(8):e1002378.
- Mugnier PD, Poirer L, Naas T, Nordmann P. Worldwide dissemination of the bla_{OXA-23} carbapenemase gene of *Acinetobacter baumannii*. Emerg Infect Dis. 2010;16(1):35–40.
- Wu W, He Y, Lu J, Lu Y, Wu J, Liu Y. Transition of bla_{OXA-58}-like to bla_{OXA-23}-like in *Acinetobacter baumannii* clinical isolates in southern China: an 8-year study. PLoS One. 2015;10(9):e0137174.
- Lolans K, Rice TW, Munoz-Price LS, Quinn JP. Multicity outbreak of carbapenem-resistant *Acinetobacter baumannii* isolates producing the carbapenemase OXA-40. Antimicrob Agents Chemother. 2006;50(9):2941–5.
- Nunez Quezada T, Rodriguez CH, Castro Canarte G, Nastro M, Balderrama Yarnui N, et al. Outbreak of bla_{OXA-72}-producing *Acinetobacter baumannii* in South America. J Chemother. 2017;29(5):321–4.
- Sari AN, Bicmen M, Gulay Z. The first report on the outbreak of OXA-24/40-like Carbapenemase-producing *Acinetobacter baumannii* in Turkey. Jpn J Infect Dis. 2013;66(5):439–42.
- Merino M, Acosta J, Poza M, Sanz F, Beceiro A, Chaves F, et al. OXA-24 carbapenemase gene flanked by XerC/XerD-like recombination sites in different plasmids from different *Acinetobacter* species isolated during a nosocomial outbreak. Antimicrob Agents Chemother. 2010;54(6):2724–7.
- Wang H, Guo P, Sun H, Wang H, Yang Q, Chen M, et al. Molecular epidemiology of clinical isolates of carbapenem-resistant *Acinetobacter* spp. from Chinese hospitals. Antimicrob Agents Chemother. 2007;51(11):4022–8.
- Lemos EV, de la Hoz FP, Alvis N, Einarson TR, Quevedo E, Castaneda C, et al. Impact of carbapenem resistance on clinical and economic outcomes among patients with *Acinetobacter baumannii* infection in Colombia. Clin Microbiol Infect. 2014;20(2):174–80.

34. Huang ST, Chiang MC, Kuo SC, Lee YT, Chiang TH, Yang SP, et al. Risk factors and clinical outcomes of patients with carbapenem-resistant *Acinetobacter baumannii* bacteremia. *J Microbiol Immunol Infect.* 2012;45(5):356–62.
35. Carlet J, Ben Ali A, Chalfine A. Epidemiology and control of antibiotic resistance in the intensive care unit. *Curr Opin Infect Dis.* 2004;17(4):309–16.
36. Chusri S, Silpapojakul K, McNeil E, Singkhamanan K, Chongsuvivatwong V. Impact of antibiotic exposure on occurrence of nosocomial carbapenem-resistant *Acinetobacter baumannii* infection: a case control study. *J Infect Chemother.* 2015;21(2):90–5.
37. Surasarak K, Narksawat K, Danchaivijitr S, Siripanichgon K, Sujirarat D, Rongrungrueng Y, et al. Risk factors for multi-drug resistant *Acinetobacter baumannii* nosocomial infection. *J Med Assoc Thai.* 2007;90(8):1633–9.
38. Kim T, Chong YP, Park SY, Jeon MH, Choo EJ, Chung JW, et al. Risk factors for hospital-acquired pneumonia caused by carbapenem-resistant gram-negative bacteria in critically ill patients: a multicenter study in Korea. *Diagn Microbiol Infect Dis.* 2014;78(4):457–61.
39. Karah N, Sundsfjord A, Towner K, Samuelsen O. Insights into the global molecular epidemiology of carbapenem non-susceptible clones of *Acinetobacter baumannii*. *Drug Resist Updat.* 2012;15(4):237–47.
40. Ruan Z, Chen Y, Jiang Y, Zhou H, Zhou ZH, Fu Y, et al. Wide distribution of CC92 carbapenem-resistant and OXA-23-producing *Acinetobacter baumannii* in multiple provinces of China. *Int J Antimicrob Agents.* 2013;42(4):322–8.
41. Tacconelli E, Cataldo MA, Dancer SJ, De Angelis G, Falcone M, Frank U, et al. ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant gram-negative bacteria in hospitalized patients. *Clin Microbiol Infect.* 2014;20(Suppl 1):1–55.
42. Johnson JK, Robinson GL, Zhao L, Harris AD, Stine OC, Thom KA. Comparison of molecular typing methods for the analyses of *Acinetobacter baumannii* from ICU patients. *Diagn Microbiol Infect Dis.* 2016;86(4):345–50.
43. Thom KA, Hsiao WW, Harris AD, Stine OC, Rasko DA, Johnson JK. Patients with *Acinetobacter baumannii* bloodstream infections are colonized in the gastrointestinal tract with identical strains. *Am J Infect Control.* 2010;38(9):751–3.
44. Morris AK, Masterton RG. Antibiotic resistance surveillance: action for international studies. *J Antimicrob Chemother.* 2002;49(1):7–10.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

